Biomednewsbreaks CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances Glioblastoma Treatment With Berubicin Amid Strong Financial Position ...
Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025 ...
Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM) Presented positive ReS ...
Trials with mice in whom the researchers implanted human glioblastoma cells have already shown that the treatment is very ...
Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment of patients ...
Northamptonshire Telegraph on MSN2d
Grieving daughters and wife dedicate days of research to dad and husband lost to incurable brain tumourTwo sisters who lost their dad to an incurable brain tumour, along with their mother, have dedicated two days of research in ...
A new study identifies key genetic vulnerabilities in glioblastoma stem cells, revealing subtype-specific dependencies that ...
Waterman is backing the charity’s calls to increase national investment in brain tumour research to £35 million per year.
Researchers have developed an innovative CAR T-cell therapy to combat glioblastoma, the most common malignant brain tumor in ...
Six main cell types form glioblastomas (GBM), the most aggressive brain cancer due to its high rate of recurrence. Of these six, quiescent cancer stem cells are responsible for resistance to therapy ...
Plenary Oral Presentation at SNO will provide latest clinical trial results from the previously enrolled INB-200 studies of autologous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback